Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 10/20 | 0.63 |
| ▸ | BRAF | P15056 | 3/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | EGFR | P00533 | 1/20 | 0.62 |
| ▸ | KRAS | P01116 | 1/20 | 0.62 |
| ▸ | RAF1 | P04049 | 1/20 | 0.62 |
| ▸ | PGR | P06401 | 1/20 | 0.62 |
| ▸ | RET | P07949 | 1/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.62 |
| ▸ | ARAF | P10398 | 1/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.62 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.62 |
| ▸ | FECH | P22830 | 1/20 | 0.62 |
| ▸ | KDR | P35968 | 1/20 | 0.62 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.62 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.62 |
| ▸ | NEK2 | P51955 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26111154 | 1.00 | CYP2C9 (0.63) | CYP2C9BRAFCYP3A4RIPK2ABCB11 | |
| SCHEMBL26111408 | 0.94 | CYP2C9 (0.55) | CYP2C9BRAFCYP3A4RIPK2ABCB11 | |
| SCHEMBL29898620 | 0.92 | BRAF (0.66) | CYP2C9BRAFCYP3A4RIPK2ABCB11 | |
| SCHEMBL26111470 | 0.92 | BRAF (0.66) | CYP2C9BRAFCYP3A4RIPK2ABCB11 | |
| SCHEMBL29898768 | 0.92 | CYP2C9 (0.64) | CYP2C9BRAFCYP3A4RIPK2ABCB11 | |
| SCHEMBL26111541 | 0.92 | CYP2C9 (0.64) | CYP2C9BRAFCYP3A4RIPK2ABCB11 | |
| SCHEMBL27101861 | 0.91 | BRAF (0.75) | CYP2C9BRAFCYP3A4RIPK2ABCB11 | |
| SCHEMBL29898626 | 0.91 | CYP2C9 (0.62) | CYP2C9BRAFCYP3A4RIPK2ABCB11 | |
| SCHEMBL29898621 | 0.91 | CYP2C9 (0.58) | CYP2C9BRAFCYP3A4RIPK2ABCB11 | |
| SCHEMBL26110843 | 0.91 | CYP2C9 (0.58) | CYP2C9BRAFCYP3A4RIPK2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228834-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF COLON AND LUNG CANCER | HEPAREGENIX GMBH (DE) | 2025-07-17 | — | — | US | disclosed |
| EP-4504185-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF COLON AND LUNG CANCER | HepaRegeniX GmbH (DE) | 2025-02-12 | — | — | EP | disclosed |
| US-11912701-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| WO-2023194443-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF COLON AND LUNG CANCER | HEPAREGENIX GMBH (DE) | 2023-10-12 | — | — | WO | disclosed |
| US-20220281864-A1 | PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | HEPAREGENIX GMBH (DE) | 2022-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912701-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | MAPK4, MAPK7, MAPK14 | CYP2C9 1742/4885BRAF 64/4885CYP3A4 637/4885 |
| US-20250228834-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF COLON AND LUNG CANCER | KRAS, MAPK4, NRAS | CYP2C9 3193/4885BRAF 27/4885CYP3A4 1490/4885 |
| US-20220281864-A1 | PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | MAPK4, MAPK7, MAPK14 | CYP2C9 1814/4885BRAF 65/4885CYP3A4 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.